Natixis Buys New Holdings in AtriCure, Inc. (NASDAQ:ATRC)

Natixis bought a new stake in AtriCure, Inc. (NASDAQ:ATRC) in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 300,000 shares of the medical device company’s stock, valued at approximately $9,126,000. Natixis owned about 0.63% of AtriCure as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also bought and sold shares of the company. Vanguard Group Inc. lifted its position in AtriCure by 0.9% during the third quarter. Vanguard Group Inc. now owns 4,689,883 shares of the medical device company’s stock worth $205,417,000 after acquiring an additional 43,431 shares during the last quarter. Assenagon Asset Management S.A. increased its holdings in shares of AtriCure by 28.0% during the fourth quarter. Assenagon Asset Management S.A. now owns 259,169 shares of the medical device company’s stock worth $9,250,000 after purchasing an additional 56,761 shares during the period. HighMark Wealth Management LLC increased its holdings in shares of AtriCure by 223.0% during the fourth quarter. HighMark Wealth Management LLC now owns 9,125 shares of the medical device company’s stock worth $326,000 after purchasing an additional 6,300 shares during the period. Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of AtriCure by 2.3% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 21,237 shares of the medical device company’s stock worth $758,000 after purchasing an additional 484 shares during the period. Finally, WCM Investment Management LLC increased its holdings in shares of AtriCure by 7.7% during the fourth quarter. WCM Investment Management LLC now owns 221,416 shares of the medical device company’s stock worth $8,133,000 after purchasing an additional 15,820 shares during the period. 99.11% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at AtriCure

In related news, insider Justin J. Noznesky sold 1,500 shares of the company’s stock in a transaction that occurred on Wednesday, May 1st. The shares were sold at an average price of $24.09, for a total transaction of $36,135.00. Following the sale, the insider now directly owns 71,284 shares in the company, valued at approximately $1,717,231.56. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In related news, insider Justin J. Noznesky sold 1,500 shares of the company’s stock in a transaction that occurred on Wednesday, May 1st. The shares were sold at an average price of $24.09, for a total transaction of $36,135.00. Following the sale, the insider now directly owns 71,284 shares in the company, valued at approximately $1,717,231.56. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Salvatore Privitera purchased 5,000 shares of the company’s stock in a transaction that occurred on Thursday, May 30th. The shares were acquired at an average price of $22.25 per share, for a total transaction of $111,250.00. Following the completion of the purchase, the insider now directly owns 103,290 shares in the company, valued at approximately $2,298,202.50. The disclosure for this purchase can be found here. 3.20% of the stock is currently owned by corporate insiders.

AtriCure Trading Down 1.9 %

ATRC stock traded down $0.46 during midday trading on Thursday, hitting $23.53. The stock had a trading volume of 1,037,495 shares, compared to its average volume of 763,531. The firm has a market cap of $1.12 billion, a P/E ratio of -29.72 and a beta of 1.44. The company has a current ratio of 4.00, a quick ratio of 2.83 and a debt-to-equity ratio of 0.16. AtriCure, Inc. has a 1-year low of $18.94 and a 1-year high of $59.61. The business has a fifty day moving average price of $22.68 and a two-hundred day moving average price of $27.46.

AtriCure (NASDAQ:ATRC) last announced its quarterly earnings data on Wednesday, May 1st. The medical device company reported ($0.25) earnings per share for the quarter, missing the consensus estimate of ($0.23) by ($0.02). AtriCure had a negative net margin of 8.98% and a negative return on equity of 7.85%. The company had revenue of $108.90 million for the quarter, compared to analyst estimates of $106.86 million. During the same quarter in the prior year, the company posted ($0.23) EPS. AtriCure’s revenue for the quarter was up 16.5% on a year-over-year basis. On average, sell-side analysts predict that AtriCure, Inc. will post -0.75 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research analysts have recently commented on ATRC shares. Oppenheimer raised shares of AtriCure from a “market perform” rating to an “outperform” rating and set a $32.00 target price on the stock in a report on Tuesday, April 23rd. StockNews.com cut shares of AtriCure from a “hold” rating to a “sell” rating in a research note on Wednesday, March 27th. Needham & Company LLC reissued a “buy” rating and issued a $40.00 price objective on shares of AtriCure in a research note on Monday, July 8th. Canaccord Genuity Group decreased their price objective on shares of AtriCure from $57.00 to $49.00 and set a “buy” rating on the stock in a research note on Thursday, May 2nd. Finally, JPMorgan Chase & Co. decreased their price objective on shares of AtriCure from $42.00 to $34.00 and set an “overweight” rating on the stock in a research note on Thursday, May 2nd. One analyst has rated the stock with a sell rating and seven have given a buy rating to the company. Based on data from MarketBeat.com, AtriCure currently has an average rating of “Moderate Buy” and a consensus target price of $49.78.

AtriCure Company Profile

AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.